In a registry study, patients with HBV or HCV who began low-dose aspirin had lower rates of HCC and 10-year liver-related mortality compared with nonusers.
Risk for 10-year liver-related mortality also lower among aspirin users with chronic hepatitis B or C.
Information on ITH can provide insight into the clonal evolutionary processes occurring within the tumor in response to prior treatment.
The median change in HCC tumor size between responders and nonresponders was statistically significant.
In this study, deterioration in specific PROs required a drop of at least 10 points from baseline.